Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Moderately to Severely Active Crohn's Disease (Phase 2/3)
2017-002195-13Phase 2Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of guselkumab in Crohn's disease (3 arms), sponsored by Janssen Pharmaceutical. Status: unknown.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2017-002195-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002195-13.